Abstract: A method of using BMP9 in combination with an NK cell and a PD-L1 antibody in preparing a medicament for treating liver cancer is provided. Specifically, BMP9 is loaded on a drug carrier microbubble to give a BMP9-carrying microbubble (MB-BMP9), and administered in combination with a natural killer cell (NK cell) and a programmed death-ligand 1 (PD-L1) antibody for treating hepatocellular carcinoma (HCC). The present invention can significantly enhance the efficacy of existing programmed death-ligand 1 (PD-L1) antibody therapies and significantly inhibit the growth of HCC cell graft tumors with significant efficacy.

Abstract: Some embodiments of the disclosure provide use of lenvatinib plus anti-PD-1 monoclonal antibody in preparation of an anti-hepatoma drug and belong to the technical field of medicine. In some embodiments, administration of the lenvatinib plus the anti-PD-1 monoclonal antibody promotes vascular “normalization” of hepatoma, while enhancing the infiltration of T lymphocytes in tumor tissue, thus significantly enhancing the therapeutic effect of hepatoma. In some embodiments, such administration may be used for the prophylaxis and treatment of the hepatoma.